CRBU Caribou Biosciences, Inc.

NASDAQ
$0.41

Caribou Biosciences, Inc. (CRBU) is confirmed to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $0.29 per share.

Caribou Biosciences Beat Consensus Estimates
Thursday, November 5, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Nov 5
Thursday · 4:05 PM ET
Earnings Whisper
-
vs ($0.29)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $0.77

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Caribou Biosciences, Inc.

Caribou Biosciences Inc. is a clinical-stage CRISPR genome-editing biopharmaceutical company. It involved in developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of both hematologic malignancies and solid tumors. Caribou Biosciences Inc. is based in BERKELEY, Calif.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.